Results 71 to 80 of about 793,394 (367)

Interview study exploring how global health partnership principles are enacted and recommendations for practice

BMJ Open
Background Effective global health partnerships can strengthen and improve health and healthcare systems across the world; however, establishing and maintaining effective partnerships can be challenging.
Lucie Byrne-Davis, Natalie Carr, Jo Hart, Rebecca Rose Turner, Eleanor Bull, Jessica Fraser   +5 more
doaj   +1 more source

Community Health Workers and Promotores in California [PDF]

, 2004
Provides an overview of, and describes the challenges facing, the emerging workforce of public health professionals who carry out a variety of health promotion, case management, and service delivery activities at the community ...
Catherine Dower, Christine Nielsen, Dennis Keane   +2 more
core  

Health Workforce for Health Equity

Medical Care, 2021
Pittman, Patricia, Chen, Candice, Erikson, Clese, Salsberg, Edward, Luo, Qian, Vichare, Anushree, Batra, Sonal, Burke, Guenevere   +7 more
openaire   +3 more sources

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

Substance Abuse Treatment, Prevention, and Policy, 2020
Background Evidence demonstrates that medications for treating opioid use disorder (MOUD) —namely buprenorphine, methadone, and extended-release naltrexone—are effective at treating opioid use disorder (OUD) and reducing associated harms.
Rebecca L. Haffajee, Barbara Andraka-Christou, Jeremy Attermann, Anna Cupito, Jessica Buche, Angela J. Beck   +5 more
doaj   +1 more source

Changing Research Perspectives on the Global Health Workforce [PDF]

Past research on the health workforce can be structured into three perspectives – “health workforce planning” (1960 through 1970s); “the health worker as economic actor” (1980s through 1990s); and “the health worker as necessary resource” (1990s through ...
David Bloom, Till Bärnighausen
core  

Talent Investments Pay Off: Executive Briefing - Advocate Health Care Realizes Returns for Investments in Education Assistance [PDF]

, 2016
An analysis of Advocate Health Care's Education Assistance Program (EAP), conducted by Accenture and partner Lumina Foundation, shows a 4-percent return on every dollar invested in tuition assistance for the health system.

core  

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

The global health workforce stock and distribution in 2020 and 2030: a threat to equity and ‘universal’ health coverage?

BMJ Global Health, 2022
Mathieu Boniol, James Campbell, Teena Kunjumen, Tapas Sadasivan Nair, Khassoum Diallo, Amani Siyam   +5 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source